A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

Clinical trial NCT06343935 · UNKNOWN

Trial details

NCT number: NCT06343935
Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.
Status: UNKNOWN
Phase: Phase 4
Study type: INTERVENTIONAL

Indolent B-cell Lymphoma

Start date: 2024-04-30
Primary completion: 2024-04-30
Enrollment: 88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.